Lexaria Bioscience Corp. announced on November 13, 2024, that it has received lead clinical site human research ethics committee (HREC) approval. This approval is for the company's Phase 1b, 12-week chronic study GLP-1-H24-4.
The study is designed to investigate Lexaria's DehydraTECH GLP-1 formulations in diabetes and weight loss over an extended period. The necessary clinical test article manufacturing for all planned study arms has already been completed.
This regulatory milestone allows Lexaria to advance its comprehensive human clinical program, moving closer to evaluating the long-term safety and efficacy of its oral drug delivery technology for GLP-1 applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.